clinical presentation, diagnosis, pathophysiology, and newly selected drugs: PCSK9 inhibitors, CETP inhibitors, MTTP inhibitors, Gemcabene, Bempedoic acid, EPA and DHA in terms of mechanism of action, statistical decrease of LDL-C levels, pharmacokinetics, effects, and side effects.